Table 2.
Multivariable Cox regression analysis of subgroups
| Variables | Overall survival | Cancer-specific survival | Recurrence-free survival | Progression-free survival | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95%CI) | p value | HR (95%CI) | p value | HR (95%CI) | p value | HR (95%CI) | p value | |
| Grouping | ||||||||
| Group 2 + Inadequate BCG | Ref | Ref | Ref | Ref | ||||
| Group 2 + Adequate BCG | 0.83 (0.72–0.95) | < 0.01 | 0.72 (0.51–1.03) | 0.07 | 0.90 (0.75–1.06) | 0.20 | 0.59 (0.41–0.86) | < 0.01 |
| Group 1 + Inadequate BCG | 0.35 (0.28–0.43) | < 0.001 | 0.63 (0.41–0.96) | 0.03 | 0.94 (0.77–1.15) | 0.55 | 1.17 (0.82–1.66) | 0.40 |
| Group 1 + Adequate BCG | 0.20 (0.16–0.26) | < 0.001 | 0.27 (0.16–0.46) | < 0.001 | 0.64 (0.52–0.78) | < 0.001 | 0.58 (0.39–0.87) | < 0.01 |
| Gender | ||||||||
| Female | Ref | Ref | Ref | Ref | ||||
| Male | 1.35 (1.15–1.59) | < 0.001 | 1.04 (0.73–1.49) | 0.83 | 1.24 (1.04–1.47) | 0.02 | 1.91 (1.29–2.85) | < 0.01 |
| Charlson Comorbidity Index | ||||||||
| 2 | Ref | Ref | Ref | Ref | ||||
| 3 | 1.46 (1.25–1.71) | < 0.001 | 0.98 (0.68–1.43) | 0.93 | 1.02 (0.86–1.21) | 0.79 | 0.81 (0.57–1.15) | 0.24 |
| 4 | 2.08 (1.69–2.57) | < 0.001 | 1.17 (0.69–1.99) | 0.55 | 0.95 (0.74–1.21) | 0.65 | 0.91 (0.55–1.51) | 0.71 |
| 5–10 | 2.71 (2.16–3.39) | < 0.001 | 1.21 (0.64–2.28) | 0.55 | 1.03 (0.77–1.38) | 0.82 | 0.83 (0.44–1.58) | 0.57 |
| Hypertension | ||||||||
| No | Ref | Ref | Ref | Ref | ||||
| Yes | 1.02 (0.88–1.18) | 0.79 | 1.16 (0.83–1.63) | 0.39 | 1.18 (1.01–1.38) | 0.04 | 0.99 (0.73–1.35) | 0.96 |
| Hyperlipidemia | ||||||||
| No | Ref | Ref | Ref | Ref | ||||
| Yes | 0.70 (0.60–0.83) | < 0.001 | 0.69 (0.46–1.04) | 0.08 | 0.88 (0.74–1.05) | 0.17 | 0.79 (0.54–1.16) | 0.23 |